According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
Data builds on promising signal published last week, underscoring the importance of sotrovimab for early treatment of COVID-19
The Institute of Pulmonology Medical Research & Development organised a symposium on early management of Covid-19
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Subscribe To Our Newsletter & Stay Updated
